BRONCHIOLITIS WITH MONTELUKAST
TO DETERMINE IMPROVEMENT IN SYMPTOMS IN 02 MONTHS TO 02 YEARS OLD CHILDREN
DOI:
https://doi.org/10.29309/TPMJ/2010.17.04.2963Keywords:
Bronchiolitis, Respiratory Syncytial Virus, Leukotriene Receptor AntagonistAbstract
Objectives: To assess the efficacy of montelukast in children with bronchiolitis. Study Design: Experimental-Preventive. Place and Duration of Study: Pediatrics department Allied/DHQ hospital affiliated with Punjab Medical College, Faisalabad, from 1st Nov 2007 to 30th April 2008. Patients and Methods: One hundred children of bronchiolitis were studied in two equal groups, group A and group B. To group A montelukast along with symptomatic treatment was given. Group B was given only symptomatic treatment. The criteria of treatment efficacy was taken as number of symptoms free days and nights, bronchiodilator rescue therapy, duration of hospital stay and complications like worsening of symptoms, ventilatory support and side effects of drug therapy. Results: Symptoms free days were increased in group A as compare to group B (P value = 0.000) whereas duration of symptoms free nights were significant numerically but not statistically. There was a significant reduction in exacerbations (P = 0.046) and use of rescue therapy (beta 2-agonist) in group A. Conclusions: Leukotriene receptor antagonist (LRTA) reduced the duration and severity of lung symptoms in children with Bronchiolitis.